CRNX — Crinetics Pharmaceuticals, Inc. stock price, charts and financials
QT61Crinetics Pharmaceuticals, Inc.Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
83.86
+0.10+0.12%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 15.23% | Shs Outstand | 105.84M | Perf Week | 0.00% |
| Market Cap | 8.88B | Forward P/E | - | EPS next Y | -4.05 | Insider Trans | -0.94% | Shs Float | 99.41M | Perf Month | 99.52% |
| Enterprise Value | 7.63B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 6.25% | Perf Quarter | 103.30% |
| Income | -465.00M | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 1.91 | Perf Half Y | 69.93% |
| Sales | 8.00M | P/B | 6.93 | EPS next Y | 13.24% | ROA | -35.42% | Short Interest | 6.21M | Perf YTD | 80.15% |
| Book/sh | 12.10 | P/C | 6.88 | EPS next 5Y | - | ROE | -43.96% | 52W High | 84.03 -0.20% | Perf Year | 201.22% |
| Cash/sh | 12.20 | P/FCF | - | EPS past 3/5Y | - | ROIC | -40.83% | 52W Low | 25.83 224.66% | Perf 3Y | 346.30% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 16.96% - | Gross Margin | 98.89% | Volatility | 0.30% 0.25% | Perf 5Y | 374.86% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | -39.02% | Oper. Margin | -3020.32% | ATR (14) | 1.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 18.56 | Sales Y/Y TTM | - | Profit Margin | -2747.18% | RSI (14) | 90.34 | Recom | 2.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.60 | EPS Q/Q | -18.27% | SMA20 | 0.13% | Beta | 0.09 | Target Price | 84.86 |
| Payout | 0.00% | Debt/Eq | 0.05 | Sales Q/Q | - | SMA50 | 49.90% | Rel Volume | 0.73 | Prev Close | 83.76 |
| Employees | 594 | LT Debt/Eq | 0.04 | Earnings | Nov 05 | SMA200 | 80.65% | Avg Volume | 3.72M | Price | 83.86 |
| IPO Date | Jul 18, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.70% 26.07% | Net Debt/EBITDA | 0.14 | Volume | 2,725,868 | Change | 0.12% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Downgrade | UBS | Buy → Neutral | $55 → $85 |
| Jul-08-26 | Reiterated | Stifel Nicolaus | $83 → $85 | |
| Jul-08-26 | Downgrade | TD Cowen | Buy → Hold | |
| Jul-08-26 | Downgrade | Evercore ISI Group | Outperform → In Line | $88 → $85 |
| Jul-07-26 | Reiterated | Robert W. Baird | $62 → $85 | |
| Jul-07-26 | Downgrade | Jefferies | Buy → Hold | $85 |
| Jul-07-26 | Downgrade | Jones Trading | Buy → Hold | |
| Jul-07-26 | Downgrade | Oppenheimer | Outperform → Perform | |
| Jul-07-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | |
| Jul-07-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $81 → $85 |
Latest News
Aug-03-26
04:52PM
04:05PM
04:00PM
Jul-28-26
Jul-28-2608:27AM
Jul-21-26
02:51PM
07:37AM
Jul-18-26
Jul-15-26
Jul-15-2611:13AM
Jul-14-26
Jul-14-2610:31AM
08:00AM
Jul-13-26
Jul-13-2602:27PM
Company
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 8 | 1 | 4 | 5 | 1 | 0 | 1 | 2 | 2 | |
| Cost of Goods Sold Incl. D&A | 1 | 0 | 0 | 0 | 0 | 57 | 1 | 24 | 9 | |
| Gross Profit | 7 | 1 | 4 | 5 | 1 | -57 | 0 | -22 | -7 | |
| Selling, General and Administrative Excl. Other | 191 | 100 | 58 | 42 | 25 | 18 | 14 | 7 | 2 | |
| Research and Development | 332 | 240 | 169 | 130 | 84 | 58 | 42 | 24 | 9 | |
| Other Operating Expense | 0 | 0 | 0 | 1 | 0 | -58 | -2 | -2 | -2 | |
| Operating Income | -517 | -339 | -223 | -168 | -108 | -75 | -54 | -29 | -9 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 52 | 40 | 8 | 4 | 0 | 1 | 3 | 2 | 0 | |
| Net Income Before Taxes | -465 | -298 | -215 | -164 | -108 | -74 | -50 | -27 | -9 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -465 | -298 | -215 | -164 | -108 | -74 | -50 | -27 | -9 | |
| Net Income From Continuing Operations | -465 | -298 | -215 | -164 | -108 | -74 | -50 | -27 | -9 | |
| Net Income | -465 | -298 | -215 | -164 | -108 | -74 | -50 | -27 | -9 | |
| EPS (Recurring) | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 | -2.42 | -2.05 | -2.23 | -0.66 | |
| EPS (Basic, Before Extraordinaries) | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 | -2.42 | -2.05 | -2.23 | -0.66 | |
| EPS (Diluted) | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 | -2.42 | -2.05 | -2.23 | -0.66 | |
| EBITDA | -461 | -296 | -213 | -163 | -107 | -74 | -49 | -28 | -9 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 546.96 | 4,141.53 | 515.91 | 190.32 | 1,079.58 | — | 602.16 | 179.94 | — | |
| Gross Margin | 87.50 | 100.00 | 100.00 | 100.00 | 100.00 | — | 0.00 | -1,100.00 | -350.00 | |
| Operating Margin | -6,462.50 | -33,900.00 | -5,575.00 | -3,360.00 | -10,800.00 | — | -5,400.00 | -1,450.00 | -450.00 | |
| Net Margin | -5,812.50 | -29,800.00 | -5,375.00 | -3,280.00 | -10,800.00 | — | -5,000.00 | -1,350.00 | -450.00 | |
| Shares Outstanding | 94 | 81 | 58 | 52 | 38 | 30 | 24 | 12 | 14 | |
| Market Capitalization | 4,376 | 4,142 | 2,064 | 952 | 1,080 | 423 | 602 | 360 | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Vivaldi Coelho Rogerio | Director | Jul 02 '26 | Sale | 40.00 | 3,000 | 120,000 | 19,225 | Jul 07 |
| Okey Stephanie | Director | Jun 17 '26 | Sale | 35.67 | 6,900 | 246,143 | 6,400 | Jun 18 |
| Knight Jeff E. | Chief Dev. & Operating Officer | Apr 08 '26 | Sale | 40.10 | 85,163 | 3,415,036 | 105,289 | Apr 10 |
| Knight Jeff E. | Chief Dev. & Operating Officer | Apr 08 '26 | Option Exercise | 22.42 | 78,434 | 1,758,818 | 190,452 | Apr 10 |
| Knight Jeff E. | Chief Operating Officer | Mar 16 '26 | Sale | 37.37 | 9,911 | 370,412 | 112,018 | Mar 18 |
| Betz Stephen F. | Chief Scientific Officer | Mar 16 '26 | Sale | 37.37 | 10,612 | 396,611 | 137,101 | Mar 18 |
| Struthers Richard Scott | President & CEO | Mar 16 '26 | Sale | 37.37 | 21,981 | 821,513 | 404,778 | Mar 18 |
| Vivaldi Coelho Rogerio | Director | Mar 12 '26 | Sale | 36.15 | 5,000 | 180,761 | 16,300 | Mar 13 |
| Schilke Tobin | Chief Financial Officer | Mar 03 '26 | Sale | 39.67 | 6,713 | 266,305 | 78,121 | Mar 04 |
| Okey Stephanie | Director | Mar 03 '26 | Sale | 39.67 | 3,000 | 119,010 | 13,300 | Mar 04 |
| Kalofonos Isabel | Chief Commercial Officer | Jan 05 '26 | Sale | 55.00 | 2,500 | 137,500 | 834 | Jan 07 |
| Kalofonos Isabel | Chief Commercial Officer | Jan 05 '26 | Option Exercise | 40.59 | 2,500 | 101,475 | 3,334 | Jan 07 |
| Betz Stephen F. | Chief Scientific Officer | Dec 26 '25 | Option Exercise | 1.91 | 18,000 | 34,380 | 117,713 | Dec 29 |
| Struthers Richard Scott | President & CEO | Dec 18 '25 | Option Exercise | 13.09 | 44,742 | 585,890 | 364,759 | Dec 18 |
| Pizzuti Dana | Chief Med and Dev Officer | Dec 01 '25 | Option Exercise | 16.89 | 5,000 | 84,450 | 71,837 | Dec 03 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.